Final overall survival (OS) analysis of a multicenter phase II study of concurrent high-dose (72Gy) three-dimensional conformal radiotherapy (3D-RT) without elective nodal irradiation with chemotherapy using cisplatin (CDDP) and vinorelbine (VNR) in patients with stage III non-small cell lung cancer (NSCLC).

Authors

Hidehito Horinouchi

Nantional Cancer Center Hospital, Tokyo, Japan

Hidehito Horinouchi , Ikuo Sekine , Minako Sumi , Toshinori Soejima , Hisayasu Nagakura , Hiroshi Isobe , Noriaki Nishiyama , Masao Harada , Naoki Ishizuka , Tomohide Tamura , Yuichiro Ohe , Miyako Satouchi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

A randomized phase II study of TS-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC): WJOG 5008L.

First Author: Takashi Seto

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

Multicenter phase II study of concurrent high-dose (72Gy) three-dimensional conformal radiotherapy (3D-CRT) without elective nodal irradiation with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small cell lung cancer (NSCLC).

First Author: Hidehito Horinouchi

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (TORG1018).

First Author: Kaoru Kubota

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Phase II study of cetuximab, pemetrexed, cisplatin and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small cell lung cancer (NSCLC): Results of the IFCT-0803 trial.

First Author: Jean Tredaniel